» Articles » PMID: 31483856

Establishing a Valid Approach for Estimating Familial Risk of Cancer Explained by Common Genetic Variants

Overview
Journal Int J Cancer
Specialty Oncology
Date 2019 Sep 5
PMID 31483856
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

We critically examined existing approaches for the estimation of the excess familial risk of cancer that can be attributed to identified common genetic risk variants and propose an alternative, more straightforward approach for calculating this proportion using well-established epidemiological methodology. We applied the underlying equations of the traditional approaches and the new epidemiological approach for colorectal cancer (CRC) in a large population-based case-control study in Germany with 4,447 cases and 3,480 controls, who were recruited from 2003 to 2016 and for whom interview, medical and genomic data were available. Having a family history of CRC (FH) was associated with a 1.77-fold risk increase in our study population (95% CI 1.52-2.07). Traditional approaches yielded estimates of the FH-associated risk explained by 97 common genetics variants from 9.6% to 23.1%, depending on various assumptions. Our alternative approach resulted in smaller and more consistent estimates of this proportion, ranging from 5.4% to 14.3%. Commonly employed methods may lead to strongly divergent and possibly exaggerated estimates of excess familial risk of cancer explained by associated known common genetic variants. Our results suggest that familial risk and risk associated with known common genetic variants might reflect two complementary major sources of risk.

Citing Articles

A scoping review of risk-stratified bowel screening: current evidence, future directions.

Cairns J, Greenley S, Bamidele O, Weller D Cancer Causes Control. 2022; 33(5):653-685.

PMID: 35306592 PMC: 8934381. DOI: 10.1007/s10552-022-01568-9.


Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy.

Park H, Seibold P, Edelmann D, Benner A, Canzian F, Alwers E Cancer Epidemiol Biomarkers Prev. 2021; 31(2):352-361.

PMID: 34862210 PMC: 9789680. DOI: 10.1158/1055-9965.EPI-21-0814.


Colorectal Cancer Risk by Genetic Variants in Populations With and Without Colonoscopy History.

Guo F, Chen X, Chang-Claude J, Hoffmeister M, Brenner H JNCI Cancer Spectr. 2021; 5(1).

PMID: 33644683 PMC: 7898082. DOI: 10.1093/jncics/pkab008.


Candidate Gene Discovery in Hereditary Colorectal Cancer and Polyposis Syndromes-Considerations for Future Studies.

Te Paske I, Ligtenberg M, Hoogerbrugge N, de Voer R Int J Mol Sci. 2020; 21(22).

PMID: 33228212 PMC: 7699508. DOI: 10.3390/ijms21228757.

References
1.
Lowery J, Ahnen D, Schroy 3rd P, Hampel H, Baxter N, Boland C . Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A state-of-the-science review. Cancer. 2016; 122(17):2633-45. PMC: 5575812. DOI: 10.1002/cncr.30080. View

2.
Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S . A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet. 2007; 39(8):984-8. DOI: 10.1038/ng2085. View

3.
Eeles R, Olama A, Benlloch S, Saunders E, Leongamornlert D, Tymrakiewicz M . Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013; 45(4):385-91, 391e1-2. PMC: 3832790. DOI: 10.1038/ng.2560. View

4.
Frampton M, Law P, Litchfield K, Morris E, Kerr D, Turnbull C . Implications of polygenic risk for personalised colorectal cancer screening. Ann Oncol. 2015; 27(3):429-34. DOI: 10.1093/annonc/mdv540. View

5.
Cox A, Dunning A, Garcia-Closas M, Balasubramanian S, Reed M, Pooley K . A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 2007; 39(3):352-8. DOI: 10.1038/ng1981. View